The FDA has asked Idenix Pharmaceuticals to submit additional safety data on its hepatitis C drug candidate IDX20963 before it can proceed with human clinical trials. "The company anticipates a delay in the initiation of the clinical program for IDX20963 while it responds to the FDA's comments," Idenix said. Idenix also halted development of two other hepatitis C drugs this year after a similar compound from Bristol-Myers Squibb was tied to heart risks.

Full Story:
Reuters, Bloomberg

Related Summaries